Loading market dashboard
Allergy Therapeutics plc
AGYTFHealthcareOTCGB
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Amazon.com Inc (NASDAQ:AMZN) and Delta Air Lines Inc (NYSE:DAL) have announced a new multi-year agreement aimed at enhancing in-flight internet connectivity...
A successful rollout of its newly launched grass-pollen treatment is ste put Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF, FRA:HHU) on the path to...
A successful rollout of its newly launched grass-pollen treatment is ste put Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF, FRA:HHU) on the path to self-sustaining profitability. That's according to Cavendish, the AIM-listed biotech's house broker, which cites management's previous commentary around peak sales potential of €100 million in Germany alone in a global market projected to reach around $1 billion by 2030.
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF, FRA:HHU), the immunotherapy company, expects commercial momentum to build through the second half of its financial year as its newly launched Grassmuno grass pollen treatment gains traction in Germany, while planning advances for a phase IIb trial of its short-course peanut allergy vaccine candidate. Grassmuno, an injected grass pollen allergen immunotherapy that received German regulatory approval during the period, launched in January 2026 and has seen a strong early response from prescribing clinicians, with the company describing it as an expected major driver of revenue in its largest market.
8:15am: Cooling tensions US stocks were set for a strong open on Tuesday as easing geopolitical tensions lifted sentiment. Dow Jones and S&P 500 futures...
